Latest Licensing Agreements News

Bio-Gene Technology Limited updates on its development of two novel insecticides, Flavocide and Qcide, highlighting regulatory progress, commercial partnerships, and a strong market outlook across multiple sectors.

Linius Technologies has secured a 12-month extension with Racing.com and reported ahead-of-schedule progress on its AI-powered proof of concept with a top European soccer league, signaling growth in sports media technology.

Critical Resources Limited has secured a 12-month exclusive option to evaluate advanced solid-state lithium-ion battery technology from the South Dakota School of Mines & Technology, aiming to enhance battery safety, performance, and commercial potential.

Livium Ltd has locked in exclusive worldwide rights to a cutting-edge microwave technology from the University of Melbourne, promising high recovery rates and energy savings in rare earth and platinum group metals extraction.

Algorae Pharmaceuticals has announced a non-renounceable Loyalty Options Offer to eligible shareholders, aiming to raise up to $337,678 before costs, with potential additional capital of $4.7 million if all options are exercised. The capital raise supports the company’s pharmaceutical and AI research and development ambitions.

Unith Ltd has secured new contracts and expanded its strategic partnerships while advancing its ISO 27001 certification, signaling strong momentum in its AI digital human technology business.

Avecho Biotechnology advances its pivotal Phase III CBD insomnia trial with 160 patients dosed and secures $2.5 million to accelerate manufacturing and regulatory efforts ahead of a 2026 interim analysis.

Linius Technologies has implemented a sweeping operational restructure, cutting expenses by more than 60% compared to FY25, while progressing a pivotal proof of concept with a major European football league and securing over $3.7 million in new funding.

Invion Limited has secured a pivotal FDA Orphan Drug Designation for its lead cancer drug INV043, bolstered its balance sheet with nearly $1.8 million in new funding, and progressed clinical trials targeting skin and anogenital cancers.

PainChek Ltd has achieved a pivotal FDA De Novo clearance for its AI-driven Adult pain assessment app, unlocking the US market and driving its annual recurring revenue to $5.6 million. The company also launched its Infant app, targeting a vast global market of pre-verbal children.

Percheron Therapeutics reports encouraging phase I clinical results for HMBD-002, confirming safety and early efficacy signals, while gearing up for a multi-arm phase II trial in 2026.

Temas Resources has completed its acquisition of ORF Technologies, gaining full ownership of the patented Regenerative Chloride Leach (RCL) technology that promises significant cost and environmental advantages in critical metals processing.